Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

Title : Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated ...

“T cell engagers are an exciting area of immunotherapy that remains in the ... The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care ...

Compared to the patient-specific nature of Autologous CAR-Ts ... When successful, this provides an opportunity for a CAR-T cell immunotherapy that is easy to supply at scale because of its ...

The TILVANCE-301 trial will compare immunotherapy plus adoptive cell ... most promising TCRT at present is the investigational autologous cell therapy IMA203 (NCT03688124), which targets the ...

The majority of autologous CAR-T cell therapies involve ... Fate Therapeutics is at the forefront of programmed cellular immunotherapy developments designed to treat cancer and immune disorders.

Immunotherapies such as immune checkpoint inhibitors and autologous chimeric antigen receptor ... explored as an alternative and promising approach to immunotherapy. Katy Rezvani, MD, PhD, said ...